AsiaMedic Ltd

AsiaMedic maintains a debt-to-equity ratio of 1.11, indicating a moderate reliance on debt financing, while its current ratio of 2.1 suggests sufficient short-term liquidity to cover obligations. The company's cash and equivalents of SGD 5,694,450 are offset by long-term debt of SGD 17,866,220, resulting in a net cash position that is negative after subtracting total debt. Free cash flow of SGD 2,135,670 and operating cash flow of SGD 3,878,580 support operational flexibility, though capital expenditures of SGD -2,676,050 indicate ongoing investment in infrastructure. Profitability metrics show a return on equity (ROE) of 12.61% and return on assets (ROA) of 4.69%, both below the industry median for healthcare facilities and services. The operating margin of 2.92% (calculated from operating income of SGD 1,029,240 on revenue of SGD 35,221,230) is also below the sector average, suggesting room for improvement in cost management. The company operates as a single segment, with all revenue derived from healthcare services in Singapore. There is no geographic diversification, and the business is entirely dependent on domestic demand for medical imaging, health screening, and wellness services. Revenue growth has been modest, with the most recent actual revenue of SGD 35,221,230 compared to an analyst estimate of SGD 12,256,000. The company's outlook for the current fiscal year shows a positive trajectory, though the pace of growth remains to be seen. The absence of a diluted share count suggests no imminent dilution pressure. Risk factors include medium liquidity risk due to the net cash position and the concentration of revenue in a single geographic market. The company's debt load and reliance on a single business model increase vulnerability to economic downturns or regulatory changes in the healthcare sector. Recent filings and transcripts indicate a focus on maintaining service quality and expanding imaging capabilities. No major capital raises or strategic acquisitions have been disclosed in the latest reports, though the company continues to invest in its core facilities.